Abstract:Fibroblast growth factor 21 (FGF-21) is a member of FGF family. Recently, it is discovered as a non-insulin-dependent cytokine to regulate blood glucose and a potential drug candidate for treatment of type 2 diabetes mellitus. However, the stability of FGF-21 is poor and its half-life in vivo is short, which severely affect its application in clinical practice. In order to solve this problem, the N-terminus of mFGF-21 was PEGylated in a site-specific manner by methoxy poly-ethylene glycol (mPEG) propionaldehydes with an average molecular mass of 20 ku for improving its biological properties including increasing half-life in vivo, and decreasing immunogenicity. The effects of pH, reaction time, protein concentrations and mass ratio between the reactants on the PEGylation of mFGF-21 were analyzed. PEG-mFGF-21 was isolated by Capto Q anion exchange chromatography or Superdex 75 gel filtration chromatography. As a result, the optimal reaction, method for mFGF-21 PEGylation and purification processes of PEG-mFGF-21 were established. Then we study the physical and chemical properties, immunogenicity, in vivo half-life, in vitro biological activity and in vivo hypoglycemic effects of PEG-mFGF-21. We found that the temperature stability and anti-protease ability of mFGF-21 were significantly improved after PEGylation. The indirect ELISA results for detection of serum antibody levels against mFGF-21 and the target protein concentration showed that PEGlyation of mFGF-21 significantly reduced its immunogenicity and increased its half-life in vivo. The glucose uptake assay results in HepG2 cells demonstrated that the in vitro activity of PEG-mFGF-21 did not decline. However, with the increment of stimulating time, the glucose uptake in cells treated with PEG-mFGF-21 significantly increased than mFGF-21. The experimental results of short-term blood glucose regulation in type 2 diabetic animals showed that the hypoglycemic speed of mFGF-21 was faster than PEG-mFGF-21, but it lasted shorter. The long-term blood glucose regulation experimental results showed that PEG-mFGF-21 had better hypoglycemic effect than mFGF-21. Surprisingly, blood glucose of PEG-mFGF-21-treated mice remained at low level for several days after the drug was withdrawn. In conclusion, under the premise of remaining its biological activity in vitro, PEGylation of mFGF-21 can improve its physical stability and anti-protease ability, decrease its immunogenicity and increase its in vivo half-life. It can also prolong the hypoglycemic effect of mFGF-21 in diabetic animals. This study provides an important technology platform for drug development of FGF-21.

Enhanced Expression and Distinctive Characterization of a Long-Acting FGF21 and Its Potential to Alleviate Nonalcoholic Steatohepatitis

Enhanced Bioactivity and Stability of a Long-Acting FGF21: A Novel Variant for the Treatment of NASH

Therapeutic Effect of Long-Acting FGF21 with Controlled Site-Specific Modification on Nonalcoholic Steatohepatitis

A Long-Acting FGF21 Alleviates Hepatic Steatosis and Inflammation in a Mouse Model of Non-Alcoholic Steatohepatitis Partly Through an FGF21-adiponectin-IL17A Pathway.

Lipidation-dimerization Platform Unlocks Treatment Potential of Fibroblast Growth Factor 21 for Non-Alcoholic Steatohepatitis

Genetic Fusion of Human FGF21 to a Synthetic Polypeptide Improves Pharmacokinetics and Pharmacodynamics in a Mouse Model of Obesity

Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis

A long‐acting FGF21 attenuates metabolic dysfunction‐associated steatohepatitis‐related fibrosis by modulating NR4A1‐mediated Ly6C phenotypic switch in macrophages

A cyclic peptide-grafted Fc with hepatocyte growth factor functionality ameliorates hepatic fibrosis in a non-alcoholic steatohepatitis mouse model

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

Pilot-scale Production and Characterization of PEGylated Human FGF-21 Analog.

Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation

The Hypoglycemic Effect of the Pegylated Fgf-21

The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates

A Better Anti-Diabetic Recombinant Human Fibroblast Growth Factor 21 (Rhfgf21) Modified With Polyethylene Glycol

[Expression and Pharmacological Evaluation of Fusion Protein FGF21-L-Fc].

Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease

Ganoderma Lucidum Polysaccharide Peptide Alleviates Hepatoteatosis via Modulating Bile Acid Metabolism Dependent on FXR-SHP/FGF.

RNA nanotherapeutics with fibrosis overexpression and retention for MASH treatment

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis

Amelioration of the Lipogenesis, Oxidative Stress and Apoptosis of Hepatocytes by a Novel Proteoglycan from Ganoderma lucidum